Lets Cure Diabetes: Society

Showing posts with label Society. Show all posts

Sunday, December 5, 2010

Diabetes Drug Could Be A Potential Treatment For Alzheimer's - Alzheimer's Society Comment

Main Category: Alzheimer's / Dementia
Also Included In: Diabetes
Article Date: 24 Nov 2010 - 1:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }());

email to a friend ?

printer friendly ?

opinions ?
not yet rated

New research claims that a drug commonly used in the treatment of type II diabetes can help treat Alzheimer's disease.

A paper published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) found that metformin can reduce the amount of the abnormal tau protein in the brains of mice. Healthy nerve cells produce tau but in Alzheimer's, the abnormal form is produced which does not function correctly.

Alzheimer's Society comment:

'Previous research has suggested that metformin reduces the risk of dementia in diabetic people, and this study provides some understanding of why this might be. The fact that the drug is safe for humans means it could potentially be tested more quickly than a completely new drug. However, further research is needed to fully understand the link between diabetes and Alzheimer's.'

'A million more people are set to develop dementia in the next 10 years. It is important that people maintain a healthy lifestyle in order to reduce their risk and that greater investment in dementia research is made to further our understanding of the condition.'

Dr Anne Corbett
Research Communications Manager

Research Reference: Professor Susann Schweiger, et al. 'The Biguanidemetformin acts on tauphosphorylation via mTOR/PP2vAsignalling', Proceedings of the National Academy of Sciences of the United States of America, November 2010.

Source:
Alzheimer's Society

Please rate this article:
(Hover over the stars
then click to rate)

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

View the original article here

Friday, November 12, 2010

Oramed Pharmaceuticals To Present Results Of An Oral Insulin Administration Study At The Tenth Annual Meeting Of The Diabetes Technology Society

Main Category: Diabetes
Also Included In: Conferences;??Pharma Industry / Biotech Industry
Article Date: 27 Oct 2010 - 2:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }());

email to a friend ?

printer friendly ?

opinions ?

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a developer of oral drug delivery systems, announced today that its work entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," will be presented at the Tenth Annual Meeting of the Diabetes Technology Society, to be held in Bethesda, Maryland this November.

"The selection of Oramed as one of the companies to present at the Diabetes Technology Conference is a great opportunity for us to appraise the diabetes science community on the important progress we have made," said Nadav Kidron, Oramed CEO.

Oramed's poster will be presented on Thursday November 11, 2010, at 5:30 PM.

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Source: Oramed Pharmaceuticals Inc.